4月17日，据CDE官网消息，南京维立志博生物科技股份有限公司联合申请药品“注射用LBL-024”，获得临床试验默示许可，受理号CXSL2500112。
公示信息显示，药品“注射用LBL-024”适应症：LBL-024单药、LBL-024联合LBL-007或特瑞普利单抗治疗晚期黑色素瘤。
南京维立志博生物科技股份有限公司，成立于2012年，位于南京市，是一家以从事专业技术服务业为主的企业。企业注册资本15650万人民币，实缴资本1701.8344万人民币。
通过天眼查大数据分析，南京维立志博生物科技股份有限公司共对外投资了3家企业，参与招投标项目2次，知识产权方面有商标信息40条，专利信息23条，此外企业还拥有行政许可27个。
主要股东信息显示，南京维立志博生物科技股份有限公司由Truman Enterprises (Hong Kong) Limited持股0.8882%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.